Absci Corporation is a biotechnology company that develops antibody therapeutics using artificial intelligence and wet lab capabilities. The company employs a data-driven approach to drug design, combining generative AI with scalable laboratory technologies to create differentiated antibody candidates. Its platform is designed to accelerate the discovery and development of therapeutic antibodies across multiple disease areas.
The company's pipeline includes four preclinical programs: ABS-101 for inflammatory bowel disease, ABS-201 for androgenic alopecia, ABS-301 for immuno-oncology, and ABS-501 for oncology. Absci has established research and development collaborations with multiple partners, including academic institutions (Memorial Sloan Kettering Cancer Center), biotech firms (Twist Bioscience, Owkin, PrecisionLife), and technology companies (Oracle Corporation, Advanced Micro Devices, Inc.).
Based in Vancouver, Washington, Absci operates with a team of 156 full-time employees. The company was founded in 2011 and is listed on Nasdaq with a market capitalization of approximately $0.4 billion. As a preclinical-stage company, revenue generation remains limited while the organization focuses on advancing its antibody discovery platform and pipeline programs.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.94 | $-0.94 | +21.7% | |
| 2023 | $-1.20 | $-1.20 | -4.3% | |
| 2022 | $-1.15 | $-1.15 | +44.7% | |
| 2021 | $-2.08 | $-2.08 | — |